Income Statement Entheon Biomedical Corp.
Equities
ENBI
CA29383X2023
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1700 CAD | -2.86% | +21.43% | +70.00% |
Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | - | - | 21.67K | 190K | 250K |
Total Revenues | - | - | 21.67K | 190K | 250K |
Cost of Goods Sold, Total | - | - | 12.54K | - | - |
Gross Profit | - | - | 9.13K | 190K | 250K |
Selling General & Admin Expenses, Total | 657K | 1.2M | 4.58M | 2.5M | 563K |
Stock-Based Compensation (IS) | - | - | 2.55M | 85.31K | 1.18K |
R&D Expenses | - | 443K | 1.49M | 1.2M | - |
Depreciation & Amortization - (IS) | - | 2.72K | 488K | 2.1K | - |
Other Operating Expenses, Total | 657K | 1.64M | 9.12M | 3.79M | 564K |
Operating Income | -657K | -1.64M | -9.11M | -3.6M | -314K |
Interest And Investment Income | - | 7.36K | 10.41K | 756 | 7.32K |
Net Interest Expenses | - | 7.36K | 10.41K | 756 | 7.32K |
Currency Exchange Gains (Loss) | - | - | - | 20.92K | -201 |
Other Non Operating Income (Expenses) | -10.37K | -8.37K | 3.05K | 250K | 2.47K |
EBT, Excl. Unusual Items | -667K | -1.64M | -9.09M | -3.33M | -304K |
Gain (Loss) On Sale Of Investments | - | 49.1K | 206K | -69.33K | 4.4K |
Gain (Loss) On Sale Of Assets | - | - | - | 1.34M | - |
Other Unusual Items | - | -2.79M | - | - | - |
EBT, Incl. Unusual Items | -667K | -4.38M | -8.89M | -2.06M | -300K |
Earnings From Continuing Operations | -667K | -4.38M | -8.89M | -2.06M | -300K |
Earnings Of Discontinued Operations | - | - | - | -6.46M | - |
Net Income to Company | -667K | -4.38M | -8.89M | -8.52M | -300K |
Net Income - (IS) | -667K | -4.38M | -8.89M | -8.52M | -300K |
Net Income to Common Incl Extra Items | -667K | -4.38M | -8.89M | -8.52M | -300K |
Net Income to Common Excl. Extra Items | -667K | -4.38M | -8.89M | -2.06M | -300K |
Per Share Items | |||||
Net EPS - Basic | -4.7 | -1.6 | -1.64 | -1.44 | -0.05 |
Basic EPS - Continuing Operations | -4.7 | -1.6 | -1.64 | -0.35 | -0.05 |
Basic Weighted Average Shares Outstanding | 142K | 2.74M | 5.43M | 5.91M | 5.91M |
Net EPS - Diluted | -5.04 | -1.6 | -1.64 | -1.44 | -0.05 |
Diluted EPS - Continuing Operations | -5.04 | -1.6 | -1.64 | -0.35 | -0.05 |
Diluted Weighted Average Shares Outstanding | 142K | 2.74M | 5.43M | 5.91M | 5.91M |
Normalized Basic EPS | -2.94 | -0.37 | -1.05 | -0.35 | -0.03 |
Normalized Diluted EPS | -2.94 | -0.37 | -1.05 | -0.35 | -0.03 |
Supplemental Items | |||||
EBITDA | - | -1.64M | -9.07M | -3.54M | - |
EBITA | -657K | -1.64M | -9.11M | -3.6M | -314K |
EBIT | -657K | -1.64M | -9.11M | -3.6M | -314K |
Total Revenues (As Reported) | - | - | - | 190K | 250K |
Normalized Net Income | -417K | -1.03M | -5.68M | -2.08M | -190K |
Supplemental Operating Expense Items | |||||
Marketing Expenses | 32.17K | - | - | - | - |
Selling and Marketing Expenses | 77.2K | - | - | - | - |
General and Administrative Expenses | 490K | 1.2M | 4.58M | 2.5M | 563K |
Research And Development Expense From Footnotes | - | 443K | 1.49M | 1.2M | - |
Net Rental Expense, Total | 14.82K | - | - | - | - |
Stock-Based Comp., Other (Total) | - | - | 2.55M | 224K | 1.18K |
Total Stock-Based Compensation | - | - | 2.55M | 224K | 1.18K |
- Stock Market
- Equities
- ENBI Stock
- Financials Entheon Biomedical Corp.
- Income Statement